S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

ETR:EVT - Evotec Stock Price, Forecast & News

€21.28
+0.23 (+1.09 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
€20.88
Now: €21.28
€21.35
50-Day Range
€18.55
MA: €19.71
€21.28
52-Week Range
€16.23
Now: €21.28
€27.29
Volume1.12 million shs
Average Volume1.36 million shs
Market Capitalization$3.18 billion
P/E Ratio52.67
Dividend YieldN/A
BetaN/A
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-40-560810

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$418.68 million
Cash Flow€1.98 per share
Book Value€3.08 per share

Profitability

Miscellaneous

Employees2,617
Market Cap$3.18 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for EVT and its competitors with MarketBeat's FREE daily newsletter.


Evotec (ETR:EVT) Frequently Asked Questions

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What price target have analysts set for EVT?

2 Wall Street analysts have issued 12 month price targets for Evotec's shares. Their forecasts range from €25.00 to €28.00. On average, they anticipate Evotec's stock price to reach €26.50 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price. View Analyst Price Targets for Evotec.

What is the consensus analysts' recommendation for Evotec?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.

Has Evotec been receiving favorable news coverage?

Headlines about EVT stock have trended somewhat negative on Wednesday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evotec earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Evotec.

Who are some of Evotec's key competitors?

What other stocks do shareholders of Evotec own?

Who are Evotec's key executives?

Evotec's management team includes the folowing people:
  • Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
  • Dr. Craig Johnstone, COO & Member of Management Board
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €21.28.

How big of a company is Evotec?

Evotec has a market capitalization of $3.18 billion and generates $418.68 million in revenue each year. Evotec employs 2,617 workers across the globe.View Additional Information About Evotec.

What is Evotec's official website?

The official website for Evotec is http://www.evotec.com/.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.


MarketBeat Community Rating for Evotec (ETR EVT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel